These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11363766)

  • 21. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
    Jacobson JM; Lederman MM; Spritzler J; Valdez H; Tebas P; Skowron G; Wang R; Jackson JB; Fox L; Landay A; Gilbert MJ; O'Neil D; Bancroft L; Al-Harthi L; Jacobson MA; Merigan TC; Glesby MJ;
    J Infect Dis; 2003 Dec; 188(12):1804-14. PubMed ID: 14673758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HIV-naive patients speak for pegylated interferon].
    Hautarzt; 2003 Jun; 54(6):517. PubMed ID: 12858854
    [No Abstract]   [Full Text] [Related]  

  • 27. [Results of two studies: Delta I/II and ACTG 175].
    Biehler GV
    Sidahora; 1996 Dec-1997 Jan; ():37-40. PubMed ID: 11363441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reevaluating initial therapy.
    Cadman J
    GMHC Treat Issues; 1998 Feb; 12(2):1-5. PubMed ID: 11365217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ddI plus d4T.
    James JS
    AIDS Treat News; 1996 Sep; (No 254):4. PubMed ID: 11363818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new nucleoside analogue.
    Torres G
    GMHC Treat Issues; 1995 Jun; 9(6):12. PubMed ID: 11362687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
    Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
    Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use and access to viral load measure assays: the need for validation.
    Agosto M
    Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3TC rules change again.
    GMHC Treat Issues; 1995 May; 9(5):2. PubMed ID: 11362412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pacing program for 3TC.
    Posit Aware; 1995; ():5. PubMed ID: 11362665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delavirdine expanded access program.
    BETA; 1996 Jun; ():7. PubMed ID: 11363651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. State of the art. Antiviral treatment of HIV infection.
    Bechtel-Boenning C
    Nurs Clin North Am; 1996 Mar; 31(1):1-13. PubMed ID: 8604373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3TC: Glaxo Wellcome broadens patient assistance.
    AIDS Treat News; 1996 Jun; (no 248):6-7. PubMed ID: 11363595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.